Aktienanalyse zu Procept Biorobotics Corp (PRCT)PRCTProcept Biorobotics Corp

PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). It designed Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that is independent of prostate size and shape and delivers resection independent of surgeon experience. It manufactures the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at its facility in San Jose, California. Each robotic system is shipped to its customers with a third-party manufactured ultrasound system and probe. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Procept Biorobotics Corp is a good buy right now due to its current price of $18.40 being significantly lower than the analyst price target of $30 set by Barclays, indicating a potential upside of 63.04%. Additionally, the company's gross margin has improved to 66.01% in Q2 2026, suggesting strong profitability potential. However, the main risk is the negative net income of -26,861,000 USD reported in Q2 2026, which highlights ongoing financial challenges.